AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06696248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol and alverine
Description: On the basis of maintaining unchanged routine hepatoprotective and symptomatic supportive treatments and the original dose of carvedilol, participants will be administered with compound alverine citrate capsules (Le Jian Su; specification: each capsule contains alverine citrate 60 mg and simeticone 300 mg; manufactured by Laboratoires MAYOLY SPINDLER), at a dosage of 180 mg/day (1 capsule orally, 3 times a day), for a continuous period of 24 weeks.
Study NCT06698029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VIM Targeting
Description: Targeting with the use of VIMRS-LAT-1.0
Study NCT06696911 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Core stability Exercises
Description: The exercises have been divided into three difficulty categories based on the level of difficulty.~Level I: When the patients were unable to sit independently, level I core stability therapy was administered. First-level exercises were done in a supine position on a plinth. The workout program mostly included side bridging movements, leg crosses, one-leg curl-ups, and straight and diagonal reaching activities. Patients can move to level once they can sit on a plinth edge unsupported for one minute while flexing their knees and hips to 90 degrees.~Level II: Exercises included straight-arm curl-ups, diagonal-arm curl-ups, and arm curl-ups with the arms crossed. The patient will go to stage three once they can sit on an unstable surface for thirty seconds.~Level III: Using a physio ball, the exercises were done while seated. The exercises performed with the ball consisted push-ups, bird dog, side Bridge, abdominal curl-ups, and bridge movements
Study NCT06696911 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Motor Imagery
Description: The motor imagery program will be performed in three steps. STEP 1 Subjects will be instructed to watch the video provided and recorded by investigator. Two types of videos will be available to watch. One recording normal movements and the other film will contain recording the patient movements. Patient will be asked to watch the video and analyze the differences.~STEP 2 In next step participants will be asked to close the eyes to focus and then to imagine how they are doing task they had previously observed 10 times.~STEP 3 Participants will be than instructed to carry out the task in verbal commands given whenever necessary. During the recall process components of movement deviating from normal will be emphasized. The difficulty level of activities and the analysis of movement components will be increased gradually according to the patient's capacity.
Study NCT06696911 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Motor Imagery
Description: The motor imagery program will be performed in three steps. STEP 1 Subjects will be instructed to watch the video provided and recorded by investigator. Two types of videos will be available to watch. One recording normal movements and the other film will contain recording the patient movements. Patient will be asked to watch the video and analyze the differences.~STEP 2 In next step participants will be asked to close the eyes to focus and then to imagine how they are doing task they had previously observed 10 times.~STEP 3 Participants will be than instructed to carry out the task in verbal commands given whenever necessary. During the recall process components of movement deviating from normal will be emphasized. The difficulty level of activities and the analysis of movement components will be increased gradually according to the patient's capacity.
Study NCT05281653 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise Training
Description: Progressive neuromuscular exercise training
Study NCT05281653 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine training sessions
Description: Routine training sessions
Study NCT06698224 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal cord transcutaneous stimulation
Description: Physical therapy combined with spinal cord transcutaneous stimulation will increase activity in the paralyzed or weak arm and hand muscles in individuals with spinal cord injury. Transcutaneous spinal cord stimulation is a non-invasive stimulation strategy and are known to facilitate recovery of lost function post spinal cord injury.
Study NCT06698224 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paired spinal cord and peripheral nerve stimulation
Description: Physical therapy combined with paired spinal cord-peripheral nerve stimulation will increase activity in the paralyzed or weak arm and hand muscles in individuals with spinal cord injury. Transcutaneous spinal cord and peripheral nerve stimulation are both non-invasive stimulation strategy and are known to facilitate recovery of lost function post spinal cord injury.
Study NCT06698081 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video Multimedia
Description: The second group will be informed of the Standard Informed Consent Form, Verbal Information, and Multimedia. In addition to the standard consent process, we planned to show a 6-minute video multimedia presentation containing information about undescended testis and orchiopexy.
Study NCT06696755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icalcaprant
Description: Oral Capsules
Study NCT06696755 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Icalcaprant
Description: Oral Capsules
Study NCT05559892 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DM-CCT
Description: Participants randomized to DM-CCT will receive cash transfers of $500 per month for 6 months, but the cash transfers will be conditional on attending a 60-minute diabetes education/skills training (30 minutes) and stress/coping (30 minutes) session delivered by trained nurses every 2 weeks for 6 months (12 sessions).
Study NCT05559892 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DM-UCT
Description: Participants randomized to UCT will receive cash transfers of $500 per month for 6 months, but there will be no conditions attached. Therefore, they will receive cash transfer payments every month. However, to control for content and attention, participants will receive mailed version of the diabetes education/skills training materials every two weeks on the same schedule as the DM-CCT telephone sessions.
Study NCT04834024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide
Description: The patients confirming to the eligibility criteria will receive MIL62 from cycle 1 to cycle 30 and lenalidomide from cycle 1 to cycle 18, unless either rapid disease progression or unacceptable toxicity was observed.
Study NCT04834024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lenalinomide
Description: The patients confirming to the eligibility criteria will receive lenalidomide for 18 cycles, unless either rapid disease progression or unacceptable toxicity was observed.
Study NCT04833933 — intervention group
Intervention type: OTHER
Intervention: Phone survey about smoking cessation process since intervention in DISCO trial
Description: We will conduct a phone survey at 2 years follow-up with a random sample of smoking patients at inclusion in DISCO trial, to know the evolution of their smoking habits, the quit attempts since the intervention and the modalities of these attempts.
Study NCT04985110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole
Description: The treatment group will receive Cotrimoxazole Forte 960 mg PO q.d. 4 hours before the biopsy procedure.
Study NCT04985110 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group will receive placebo q.d. 4 hours before the biopsy procedure.
Study NCT05356429 — intervention group
Intervention type: OTHER
Intervention: Small molecule LCDM
Description: The cocktail of small molecules includes four chemical components of LCDM were added to GV oocyte culture medium.
Study NCT05476731 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: culture and antifungal sensitivity and molecular detection
Description: Samples will be cultured on Modified Dixon media for 10 days at temperature between 32-34°C.Molecular detection of malassezia species by Restriction Fragment Length Polymorphism (RFLP) .~Antifungal susceptibility testing of the isolates will be performed using the following antifungals Fluconazole, AmphotericinB and Fluocytosine
Study NCT04898309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNR-038, 50 МЕ/ kg
Description: A single intravenous infusion of GNR-038, 50 МЕ/ kg less than 5 hours after the onset of edema.
Study NCT04898309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNR-038, 100 МЕ/ kg
Description: A single intravenous infusion of GNR-038, 100 МЕ/ kg less than 5 hours after the onset of edema.
Study NCT04898309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berinert®, 20 МЕ/ kg
Description: A single intravenous infusion of Berinert®, 20 МЕ/ kg less than 5 hours after the onset of edema.
Study NCT04898309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A single intravenous infusion of Placebo less than 5 hours after the onset of edema.
Study NCT04898309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNR-038. The dose will be selected according to results of stage 1 clinical trial.
Description: A single intravenous infusion of GNR-038 less than 5 hours after the onset of edema.
Study NCT04547296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate Ringer's Solution
Description: After the participants enter the operating room, radial artery puncture and catheterization were performed. The blood gas in the non-oxygen state was used as the basic value. A peripheral venous access was established in one upper limb, and the two groups were pre-dilated with sodium bicarbonate Ringer's solution or acetate Ringer's solution (30 min, 8 ml/kg). For laparoscopic surgery, adjust the PaCO2 value to 35-45 mmHg again 10 minutes after the establishment of the pneumoperitoneum. After the operation started, the two groups of participants were maintained with 4-5 ml/kg/h Ringer's solution during the operation. Blood gas was measured every hour after tracheal intubation during the operation, and the last blood gas was measured when the skin was sutured. When the blood gas pH \<7.2, 5% sodium bicarbonate injection was given to correct it.
Study NCT05454189 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reduced IPD Flush Schedule
Description: IPD flush every 12 weeks
Study NCT05454189 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard IPD Flush Schedule
Description: IPD flush every 4 weeks
Study NCT04784169 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: free middle turbinate flap
Description: Repairing low flow leak using free middle turbinate flap
Study NCT04784169 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: vascularized nasoseptal flap
Description: Repairing low flow leak using fascia lata
Study NCT06316180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: drospirenone/estetrol 3mg/14.2mg
Description: Hysteroscopic polipectomy after starting 14-day treatment with oral drospirenone/estetrol 3mg/14.2mg at any time of the menstrual cycle.
Study NCT05285358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT05285358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV
Study NCT05285358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given via PIPAC
Study NCT05285358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05285358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06471725 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: combination of pilates exercises, Low-level laser therapy, and low-intensity ultrasound
Description: The core and hip muscles will be targeted through a customized workout program consisting of exercises such as Breathing, Planks, Side- Planks, Weighted lunges, Glute Bridge, Clamshell, Half-Kneeling Hip Flexor Stretch, Swan dive, Roll down, Ab curls, and Shoulder bridge, Low-intensity Ultrasound , and low level laser therapy
Study NCT06471725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combination of pilates exercises, Low-level laser therapy, and low-intensity ultrasound
Description: The core and hip muscles will be targeted through a customized workout program consisting of exercises such as Breathing, Planks, Side- Planks, Weighted lunges, Glute Bridge, Clamshell, Half-Kneeling Hip Flexor Stretch, Swan dive, Roll down, Ab curls, and Shoulder bridge, Low-intensity Ultrasound , and low level laser therapy
Study NCT05621460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 50mL still water
Description: Drink 50mL still water immediately prior to head-up tilt test
Study NCT04632381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zotatifin
Description: Zotatifin is a potent and sequence-selective inhibitor of eukaryotic translation initiation factor (eIF) 4A1-mediated translation that imparts its regulation through a reversible enhancement of eIF4A1 binding to RNAs (ribonucleic acids) with specific polypurine motifs within the 5'-untranslated region (UTR).
Study NCT04632381 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5% dextrose injection, USP
Study NCT05179005 — intervention group
Intervention type: DEVICE
Intervention: RibFix Advantage
Description: Intrathoracic rib fracture stabilization
Study NCT06549907 — intervention group
Intervention type: OTHER
Intervention: Multi-omics testing
Description: Samples include tissue, blood, urine and stool, and multi-omics approaches include single-cell sequencing, spatial transcriptome sequencing, macro transcriptome sequencing, whole exome sequencing, microproteomics, immunohistochemistry, and multiplex fluorescence immunohistochemistry.
Study NCT06549907 — intervention group
Intervention type: OTHER
Intervention: MRI
Description: MRI will be conducted to investigate image characteristics during treatment
Study NCT06421454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Pressure Ulcer will be treated with a melatonin cream daily
Study NCT06421454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrogel
Description: Pressure ulcer will be treated with hydrogel daily as a comparator
Study NCT06057103 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ZX-7101A
Description: ZX-7101A Tablets single dose tablet, 80 mg, Oral
Study NCT06057103 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oseltamivir
Description: Oseltamivir phosphate capsule was administered as a single drug, 75 mg twice daily, for 5 days,Oral
Study NCT06057103 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ZX-7101A and Oseltamivir
Description: ZX-7101A tablet (80mg, single dose) was combined with oseltamivir phosphate capsule (75 mg twice daily),Oral
Study NCT03188380 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Plain abdominal radiography
Description: After meeting enrolment criteria each patient will have an AR performed. One image will be obtained with a vertical beam and a horizontal beam, with the patient supine.
Study NCT03188380 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Abdominal ultrasound
Description: If the AR is inconclusive or no abnormalities typical for NEC are recorded, an AUS will be ordered.
Study NCT06571006 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music
Description: The musical intervention will start 10 minutes before the lumbar puncture procedure begins and continue for another 20 minutes after the intervention. Babies will be kept away from noise during this study. W.A. It was decided to use the piece Adagio from the Violin Concerto No. 3 in G major, KV 216, composed by Mozart. The track will be played through two speakers on opposite sides, 30 cm away from the baby's ears, to optimize sound perception. High quality digital audio will be used to make babies listen. Music will be played at a level that can be heard in high noise pollution (i.e. the noise of incubator operation and the white noise of the recorder), but taking into account the permissible sound level recommended by the American Academy of Pediatrics, i.e. 65-70 dB
Study NCT06569784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]HSK31858
Description: A single oral dose of 40 mg/120 μCi \[14C\]HSK31858 after fasting for at least 10 hours.
Study NCT04478734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moderate doses of Thiamine y Biotin
Description: Thiamine 600 mg every day + Biotin 150mg every day
Study NCT04478734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High doses of Thiamine y Biotin
Description: Thiamine 1200 mg every day + Biotin 300mg every day
Study NCT04985149 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electromyographic measurement:
Description: Nerve conduction studies; assesses nerve function and includes motor, sensory, and mixed nerve tests.~Micromed (Italy 2020) EMG device will be used in the electrophysiological examination. Sensory and motor conduction studies will be performed in the lower and upper extremities by paying attention to the extremity temperatures of the cases.~Nerve conduction studies will be performed by another physician who is unaware of the diagnosis of the patients. Bilateral lower extremity sural sensory responses of the patients will be taken.~In the antidromic method in sural nerve conduction examination, the bipolar superficial electrode is placed behind the lateral malleolus; stimulation will be made with bipolar surface electrodes 12-15 cm proximal to the recording site. Initial latency should be \< 3.8 ms, amplitude > 10 Mv, and conduction velocity > 36 m/sec in sensory response of the sural nerve.
Study NCT04985149 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasonographic measurement:
Description: Sural nerve ultrasonography (US) will be performed by another clinician (Merve Akdeniz leblebicier) who is experienced in musculoskeletal ultrasonography and unaware of clinical evaluation, using a 6-18 Mhz linear probe. (Mindray -UMT 200, United States) Both sural nerve joints of the patients will be evaluated. The patient will lie on the stretcher in the prone position, the ankle will be out of the bed. The 14 cm above the malleolus will be marked as the main line, the nerve will be detected in the lateral of the tendon of the gastrocnemius muscle and the proximal of the saphenous vein. Nerve diameter measurement will be measured 3 times in mm2 and the average will be taken. Then, possible inflammatory pathologies will be ruled out by providing clinical confirmation using the Doppler mode (11).
Study NCT05838716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT05838716 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT05838716 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D Vitamin
Description: Given PO
Study NCT05838716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual X-ray Absorptiometry
Description: Undergo DXA scan
Study NCT05838716 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Dual X-ray Absorptiometry
Description: Undergo DXA scan
Study NCT05838716 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT05838716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05838716 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05838716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05838716 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06067789 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neuraxial anesthesia
Description: Intervention arm participants will be allocated to neuraxial anesthesia.
Study NCT05066139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EPODIG-G program (coordination of supportive care)
Description: EPODIG-G program includes: a nutritional evaluation (laboratory tests: albumin, pre-albumin, C reactive protein and vitamin D dosage, nutritional status, Handgrip test, Simple Evaluation of Food Intake (SEFI), spontaneous food intake evaluation) ; a medication reconciliation ; physical therapy (Six Minute Walk Test)
Study NCT04727164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBM4003 and Triprilimab
Description: Subjects will be treated with HBM4003 on Day 1 Cycle 1 and be treated with HBM4003 and Triprilimab during each 21-day cycles from Cycle 2 in part 1.Subjects will be treated with HBM4003 and Triprilimab on Day 1 during each 21-day cycle in part 2.
Study NCT05810649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Freshly manufactured 35 kDa hyaluronan fragment
Description: One hundred milligrams of the freshly made 35 kDa low molecular weight HA fragment HA35 was injected into the tissue under the heath skin immediately surrounding the chronic wounds once a day for 10 days.The pain associated with the wounds and degree of wound healing, including the size of the fresh granulation area on the wound; the degree to which the surface of the skin surrounding the wound was dark, red, dry or broken; and the size of the wound, were observed and recorded.